Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]β-CIT SPECT

American Journal of Psychiatry

Volumn 161, Issue 12, 2004, Pages 2201-2206

  Van Der Wee, Nic J ^a,b   Stevens, Henk ^a   Hardeman, Johannes A ^a   Mandl, Rene C ^a   Denys, Damiaan A ^a   Van Megen, Harold J ^a   Kahn, René S ^a   Westenberg, Herman M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 BETA CARBOMETHOXY 3 BETA (4 IODOPHENYL)TROPANE I 123; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE TRANSPORTER; IODINE 123; PSYCHOTROPIC AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN; CAUDATE NUCLEUS; CLINICAL ARTICLE; COMORBIDITY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; FEMALE; HEMISPHERE; HUMAN; ISOTOPE LABELING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ADULT; BRAIN; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTROPIC DRUGS; PUTAMEN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 9744284965     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.161.12.2201     Document Type: Article

References (40)

1. Regier DA, Narrow WE, Rae DS: The epidemiology of anxiety disorders: the Epidemiologic Catchment Area (ECA) experience. J Psychiatr Res 1990; 24(suppl 2)3-14
2. Stein MB, Forde DR, Anderson G, Walker JR: Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Am J Psychiatry 1997; 154:1120-1126
3. Baumgarten HG, Grozdanovic Z: Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35:13-20
4. Pian KL, Westenberg HG, van Megen HJ, den Boer JA: Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) 1998; 140:365-370
5. Khanna S, John JP, Reddy LP: Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology 2001; 26:209-223
6. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57:794-801
7. Denys D, van Megen H, Westenberg H: Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002; 63:700-703
8. Tiihonen J, Kuoppamaki M, Nagren K, Bergman J, Eronen E, Syvalahti E, Hietala J: Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 1996; 126:277-280
9. McGrath MJ, Campbell KM, Burton FH: The role of cognitive and affective processing in a transgenic mouse model of cortical-limbic neuropotentiated compulsive behavior. Behav Neurosci 1999; 113:1249-1256
10. Swedo SE, Leonard HL, Kruesi MJ, Rettew DC, Listwak SJ, Berrettini W, Stipetic M, Hamburger S, Gold PW, Potter WZ: Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:29-36
11. Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A: Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. Biol Psychiatry 1997; 42:889-897
12. Insel TR: Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:739-744
13. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brucke T: Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder-implications for psychopharmacology. World J Biol Psychiatry 2002; 3:133-146
14. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brucke T: beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995; 100:247-256
15. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13:295-309
16. Kuikka JT, Tiihonen J, Bergstrom KA, Karhu J, Hartikainen P, Viinamaki H, Lansimies E, Lehtonen J, Hakola P: Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 1995; 22:346-350
17. 123I]beta- CIT: binding kinetics in the human brain. J Neural Transm Gen Sect 1993; 94:137-146
18. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
19. Oldfield RC: The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychologia 1971; 9:97-113
20. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 1989; 46:1006-1011
21. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 1989; 46:1012-1016
22. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
23. 11C]DASB PET imaging study. Am J Psychiatry 2001; 158:1843-1849
24. Collins DL, Neelin P, Peters TM, Evans AC: Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 1994; 18:192-205
25. MacDonald JD: Register, McGill University. Quebec, Montreal Neurological Institute, McConnell Brian Imaging Centre, 1993
26. Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O, Peurasaari J, Räkköläinen V, Syvälahti E, Hietala J: Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry 2000; 157:269-271
27. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, Innis RB: Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002; 10:36-43
28. Bartko JJ, Carpenter WT Jr. On the methods and theory of reliability. J Nerv Ment Dis 1976; 163:307-317
29. Denys D, van Megen H, Westenberg H: The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2002; 17:109-114
30. Heinz A, Knable MB, Wolf SS, Jones DW, Gorey JG, Hyde TM, Weinberger DR: Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology 1998; 51:1069-1074
31. Saxena S, Brody AL, Schwartz JM, Baxter LR: Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998; 35:26-37
32. Mozley LH, Gur RC, Mozley PD, Gur RE: Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001; 158:1492-1499
33. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG: Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998; 95:4029-4034
34. Jaber M, Jones S, Giros B, Caron MG: The dopamine transporter: a crucial component regulating dopamine transmission. Mov Disord 1997; 12:629-633
35. 11C]raclopride and PET in normal human subjects. Am J Psychiatry 1997; 154:490-496
36. Di Giovanni G, Di Matteo V, Di Mascio M, Esposito E: Preferential modulation of mesolimbic vs nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse 2000; 35:53-61
37. Gervais J, Rouillard C: Dorsal raphe stimulation differentially modulates dopaminergic neurons in the ventral tegmental area and substantia nigra. Synapse 2000; 35:281-291
38. Leckman JF, Grice DE, Boardman J, Zhang H, Vitale A, Bondi C, Alsobrook J, Peterson BS, Cohen DJ, Rasmussen SA, Goodman WK, McDougle CJ, Pauls DL: Symptoms of obsessive-compulsive disorder. Am J Psychiatry 1997; 154:911-917
39. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey JG, Lee KS, Linnoila M, Weinberger DR: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22:133-139
40. 123I]-beta- CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 2000; 47:482-489